Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Study Summary

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

Conditions

Clear Cell Renal Cell Carcinoma

Interventions / Drugs

XmAb819

View on ClinicalTrials.gov ↗

Sponsor

XNCR

Xencor Inc

Bispecific Antibodies

D38/100

Study Details

Enrollment307 participants

Primary Completion—

Lead SponsorXencor, Inc.

Data Retrieved2026-04-11 04:31:58.925875+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.